Lv511
810 积分 2025-07-09 加入
Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort
2天前
已完结
Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy
6天前
已完结
Advances in Androgen Deprivation Therapy-Sparing Strategies: Ongoing Studies in Metastatic Castration-Sensitive Prostate Cancer
7天前
已完结
Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes
26天前
已完结
Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients
27天前
已完结
249例高危和极高危非转移性前列腺癌患者胚系基因检测结果分析与解读
27天前
已完结
Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study
1个月前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
1个月前
已完结
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
1个月前
已完结
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
2个月前
已关闭
皖公网安备34019202002308
